Overview

  • Product nameAnti-MEK1 antibody
    See all MEK1 primary antibodies
  • Description
    Rabbit polyclonal to MEK1
  • SpecificityNo cross reactivity with other proteins.
  • Tested applicationsSuitable for: WB, IHC-P, ICCmore details
  • Species reactivity
    Reacts with: Rat, Human
    Predicted to work with: Mouse, Rabbit, Chicken, Cow, Dog, Pig
  • Immunogen

    Synthetic peptide corresponding to Human MEK1 aa 353-367 (C terminal).
    Sequence:

    KQLMVHAFIKRSDAE


    Database link: Q02750

  • Positive control
    • Rat thymus tissue lysate, Rat skeletal muscle tissue lysate, Rat kidney tissue lysate, Rat lung tissue lysate, CEM whole cell lysate, Colo320 whole cell lysate.

Properties

Applications

Our Abpromise guarantee covers the use of ab109556 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 43 kDa.
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
ICC Use a concentration of 1 µg/ml.

Target

  • FunctionCatalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
  • Tissue specificityWidely expressed, with extremely low levels in brain.
  • Involvement in diseaseDefects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
  • Sequence similaritiesBelongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
    Contains 1 protein kinase domain.
  • Post-translational
    modifications
    Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
    Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
  • Information by UniProt
  • Database links
  • Alternative names
    • Dual specificity mitogen activated protein kinase kinase 1 antibody
    • Dual specificity mitogen-activated protein kinase kinase 1 antibody
    • ERK activator kinase 1 antibody
    • MAP kinase kinase 1 antibody
    • MAP kinase/Erk kinase 1 antibody
    • MAP2K1 antibody
    • MAPK/ERK kinase 1 antibody
    • MAPKK 1 antibody
    • MAPKK1 antibody
    • MEK 1 antibody
    • Mek1 antibody
    • MEKK1 antibody
    • Mitogen activated protein kinase kinase 1 antibody
    • MKK 1 antibody
    • MKK1 antibody
    • MP2K1_HUMAN antibody
    • PRKMK1 antibody
    • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1) antibody
    • Protein kinase mitogen activated, kinase 1 antibody
    see all

Anti-MEK1 antibody images

  • All lanes : Anti-MEK1 antibody (ab109556) at 1 µg/ml

    Lane 1 : Rat thymus tissue lysate
    Lane 2 : Rat skeletal muscle tissue lysate
    Lane 3 : Rat kidney tissue lysate
    Lane 4 : Rat lung tissue lysate
    Lane 5 : CEM whole cell lysate
    Lane 6 : Colo320 whole cell lysate


    Predicted band size : 43 kDa

References for Anti-MEK1 antibody (ab109556)

ab109556 has not yet been referenced specifically in any publications.

Product Wall

Application Western blot
Sample Mouse Tissue lysate - whole (Muscle)
Loading amount 50 µg
Specification Muscle
Treatment Different treatments
Gel Running Conditions Reduced Denaturing (10)
Blocking step 2.5%BSA + 2.5% Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 2.5% · Temperature: RT°C
Username

Abcam user community

Verified customer

Submitted May 30 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"